Decreased Time to Viral Suppression After Implementation of Targeted Testing and Immediate Initiation of Treatment of Acute Human Immunodeficiency Virus Infection Among Men Who Have Sex With Men in Amsterdam
Open Access
- 5 May 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 72 (11), 1952-1960
- https://doi.org/10.1093/cid/ciaa505
Abstract
Men who have sex with men (MSM) with acute human immunodeficiency virus (HIV) infection (AHI) are a key source of new infections. To curb transmission, we implemented a strategy for rapid AHI diagnosis and immediate initiation of combination antiretroviral therapy (cART) in Amsterdam MSM. We assessed its effectiveness in diagnosing AHI and decreasing the time to viral suppression. We included 63 278 HIV testing visits in 2008–2017, during which 1013 MSM were diagnosed. Standard of care (SOC) included HIV diagnosis confirmation in < 1 week and cART initiation in < 1 month. The AHI strategy comprised same-visit diagnosis confirmation and immediate cART. Time from diagnosis to viral suppression was assessed for 3 cART initiation periods: (1) 2008–2011: cART initiation if CD4 < 500 cells/μL (SOC); (2) January 2012–July 2015: cART initiation if CD4 < 500 cells/μL, or if AHI or early HIV infection (SOC); and (3a) August 2015–June 2017: universal cART initiation (SOC) or (3b) August 2015–June 2017 (the AHI strategy). Before implementation of the AHI strategy, the proportion of AHI among HIV diagnoses was 0.6% (5/876); after implementation this was 11.0% (15/137). Median time (in days) to viral suppression during periods 1, 2, 3a, and 3b was 584 (interquartile range [IQR], 267–1065), 230 (IQR, 132–480), 95 (IQR, 63–136), and 55 (IQR, 31–72), respectively (P < .001). Implementing the AHI strategy was successful in diagnosing AHI and significantly decreasing the time between HIV diagnosis and viral suppression.Keywords
Funding Information
- Aids Fonds (2013169)
- Bristol-Myers Squibb International Corporation (AI424-541)
- Gilead Sciences Europe Ltd (PA-HIV-PREP-16–0024)
- Gilead Sciences (CO-NL-276–4222, CO-US-276–1712)
- Janssen Pharmaceuticals (PHNL/JAN/0714/0005b/1912fde)
- ZonMw (522002003)
- Stichting HIV Monitoring
- Dutch Ministry of Health, Welfare and Sport
- National Institute for Public Health and the Environment
This publication has 34 references indexed in Scilit:
- Screening Yield of HIV Antigen/Antibody Combination and Pooled HIV RNA Testing for Acute HIV Infection in a High-Prevalence PopulationJAMA, 2016
- Sources of HIV infection among men having sex with men and implications for preventionScience Translational Medicine, 2016
- Impact of nucleic acid testing relative to antigen/antibody combination immunoassay on the detection of acute HIV infectionAIDS, 2015
- Targeting screening and social marketing to increase detection of acute HIV infection in men who have sex with men in Vancouver, British ColumbiaAIDS, 2013
- ru2hot?: A public health education campaign for men who have sex with men to increase awareness of symptoms of acute HIV infectionSexually Transmitted Infections, 2013
- Impact of Multi-Targeted Antiretroviral Treatment on Gut T Cell Depletion and HIV Reservoir Seeding during Acute HIV InfectionPLOS ONE, 2012
- Prevention of HIV-1 Infection with Early Antiretroviral TherapyThe New England Journal of Medicine, 2011
- The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling studyThe Lancet, 2011
- Acute HIV-1 InfectionThe New England Journal of Medicine, 2011
- Dynamics of HIV viremia and antibody seroconversion in plasma donorsAIDS, 2003